| Description |
1 online resource (xxi, 412 pages) : illustrations (some color) |
| Series |
Current multidisciplinary oncology series |
|
Current multidisciplinary oncology.
|
| Contents |
Part I: Epidemiology, screening, and diagnosis -- Introduction: the multidisciplinary approach to prostate cancer -- Epidemiology of prostate cancer -- Diet and prostate cancer -- Epidemiology: obesity as a risk factor -- Screening and diagnosis: the pros of PSA screening -- The argument against prostate cancer screening -- How do we improve PSA accuracy? -- Screening and diagnosis: an update on the ISUP-modified Gleason score and its controversies -- Evaluation of distant disease: the utility of nuclear imaging -- Current approaches to prostate cancer staging and risk stratification: in the midst of a paradigm shift -- Novel molecular and genotype profiling in prostate cancer: the future of screening, diagnosis, and staging -- Genomics and risk assessment -- Future direction: novel urine and serum markers -- Morphometric and systems pathology: the future of screening, diagnosis, and staging -- PET: the future of screening, diagnosis, and staging for prostate cancer -- DCE MRI and MR spectroscopy: the future of screening, diagnosis, and staging -- Future direction: contrast ultrasound -- Counseling patients with clinically localized, high-risk prostate cancer -- Part II: Treatment for low-risk, localized disease -- Active surveillance for prostate cancer: an overview -- Treatment of low-risk, localized prostate cancer: a holistic approach with diet -- Traditional radical prostatectomy -- Laparoscopic radical prostatectomy: techniques and complications -- Robotic radical prostatectomy: the Thomas Jefferson University experience -- Surgical training, digital capture, virtual reality, and the future of radical prostatectomy -- External beam radiation therapy: conventional fractionation -- Hypofractionated radiation therapy for localized prostate cancer -- Stereotactic body radiation therapy for localized prostate cancer -- Treatment of low-risk, localized prostate cancer: use of proton therapy -- Treatment of low-risk, localized prostate cancer: brachytherapy -- Treatment of low-risk, localized prostate cancer: general principles of ablative and focal therapies -- Hyperthermia for prostate cancer -- Ablative techniques: vascular targeted photodynamic therapy -- Laser ablative techniques for prostate cancer -- Irreversible electroporation (IRE) prostate ablation -- Quality of life with surgery -- Quality of life with androgen deprivation therapy -- Quality of life with external beam radiation therapy -- Quality of life with brachytherapy for low-risk localized prostate cancer -- Role for comparative effectiveness research in treatment decision making -- Defining treatment failure for localized prostate cancer: PSA and beyond -- Prognosis after biochemical failure and surrogate endpoints for prostate cancer-specific mortality -- Part III: Treatment for high-risk, localized, and locally advanced disease -- treatment of high-risk prostate cancer: the role of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy -- Part IV: Treatment of disseminated disease -- Salvage therapy for rising PSA -- Metastatic hormone sensitive prostate cancer -- Metastatic castrate-resistant prostate cancer: mechanisms of hormone escape -- Metastatic castrate-resistant prostate cancer: role of chemotherapy and multifaceted treatment paradigms -- Metastatic castrate-resistant prostate cancer: role of androgen signaling inhibitors -- Radiation and the immune system -- Immunotherapy: agents targeting prostate cancer -- Treatment of bony metastases: inhibitors of bone resorption -- Treatment of bone metastases: radiopharmaceuticals -- Prognostication of metastatic castration-resistant prostate cancer |
| Summary |
"With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice"--Publisher's description |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Online resource; title from resource home page (ebrary, viewed November 2, 2015) |
| Subject |
Prostate -- Cancer -- Diagnosis
|
|
Prostate -- Cancer -- Treatment
|
|
Health care teams.
|
|
Prognosis.
|
|
Prostate-specific antigen.
|
|
Prostatic Neoplasms -- diagnosis
|
|
Early Detection of Cancer
|
|
Patient Care Team
|
|
Prognosis
|
|
Prostate-Specific Antigen
|
|
Prostatic Neoplasms -- therapy
|
|
HEALTH & FITNESS -- Diseases -- Cancer.
|
|
MEDICAL -- Oncology.
|
|
Prostate-specific antigen
|
|
Prognosis
|
|
Health care teams
|
|
Prostate -- Cancer -- Diagnosis
|
|
Prostate -- Cancer -- Treatment
|
| Form |
Electronic book
|
| Author |
Dicker, Adam P., editor.
|
|
Kelly, Wm. Kevin (William Kevin), editor.
|
|
Zaorsky, Nicholas G., editor, illustrator.
|
|
Trabulsi, Edouard J., editor.
|
| ISBN |
9781617051067 |
|
1617051063 |
|
